Drug Classes Archives - Page 4 of 96

RedHill pill shows promise vs Omicron; mRNA vaccines appear effective in those with well-controlled HIV

Antibiotics, Antiretroviral Therapy, BNT162b2 (Pfizer and BioNTech), Coronavirus Vaccines, COVID-19 Studies, COVID-19 treatment pill, Gilead, HIV, Hospitalized COVID-19 Patients, JAMA, Messenger RNA (mRNA) Vaccines, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Omicron (B.1.1.529) (South Africa), R&D, Remdesivir, Steroids

An experimental drug being developed by RedHill Biopharma Ltd. that improved outcomes in a randomized trial involving severely ill COVID-19 patients infected with earlier versions of the coronavirus is showing promise against the Omicron variant in test tube experiments, researchers said. Additionally, people living with well-controlled HIV infections are likely to have immune responses to the mRNA COVID-19 vaccines from Moderna and from Pfizer/BioNTech similar to those of otherwise healthy individuals, according to new data.

April 11, 2022/by Reuters Health

mRNA in the spotlight as BioNTech finally makes a splash in cancer

BioNTech, Cancer Vaccines, CAR-T Therapy, Clinical Data, Clinical Trials, COVID-19 Vaccines, Messenger RNA (mRNA) Therapeutics, Messenger RNA (mRNA) Vaccines, Moderna, R&D, Solid Tumors, University of Pennsylvania (Penn)

At the Clinical Trials Plenary Session at the 2022 AACR Annual Meeting, Dr. John Haanen, M.D., Ph.D., of the Netherlands Cancer Institute presented data from BioNTech’s ongoing first-in-human Phase I/II trial of the company’s CAR-T cell therapy BNT211 in patients with advanced solid tumors.

April 11, 2022/by BioSpace

Lilly’s lebrikizumab combined with topical corticosteroids showed significant improvements in disease severity for atopic dermatitis

Atopic Dermatitis, Clinical Data, Clinical Trial Endpoints, Clinical Trials, Corticosteroids, Cytokines, Dermatological Diseases, Eli Lilly, Interleukin-13, Placebo, R&D, Secondary Endpoints

At 16 weeks, 70 percent of patients with moderate-to-severe atopic dermatitis receiving the investigational IL-13 inhibitor lebrikizumab combined with standard-of-care topical corticosteroids (TCS) achieved at least 75 percent improvement in overall disease severity (EASI-75*) in the ADhere trial, Eli Lilly and Company announced April 11 at the 4th Annual Revolutionizing Atopic Dermatitis Conference.

April 11, 2022/by PR Newswire

Boehringer Ingelheim announced the company’s intention to pump €25 billion ($27 billion) into its R&D pipeline over the next five years.

April 6, 2022/by BioSpace

FDA pulls authorization for GSK-Vir’s COVID therapy as BA.2 cases rise

Antibody Therapies, COVID-19 cases, Covid-19 Data, Emergency Use Authorization (EUA), FDA, GlaxoSmithKline, Omicron BA.2, Shares, Sotrovimab, Therapeutics, U.S. Securities and Exchange Commission (SEC), Vir Biotechnology

The U.S. health regulator said on April 5 GlaxoSmithKline and Vir Biotechnology’s antibody therapy was no longer authorized as a COVID-19 treatment, with data suggesting it was unlikely to be effective against the dominant Omicron sub-variant in the country.

April 5, 2022/by Reuters Health

With mRNA Advancing, Bancel Tells Friends “Don’t Die” in Next 10 Years

Business, Clinical Trials, Cytomegalovirus, Epstein-Barr Virus, Flu Vaccines, Foundations, Herpes Simplex Virus, Messenger RNA (mRNA) Vaccines, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), R&D

Moderna’s CEO Stéphane Bancel spoke at the Boston College Chief Executives Club on April 5. While COVID-19 vaccine production was a big talking point for the leader of Moderna, he also touched on how mRNA technology can usher us into a longer life span, saying that he tells all of his friends to “not die” in the next ten years.

April 5, 2022/by Andrew Humphreys

Theravance Narrows Focus to Multiple System Atrophy Subset Following Mixed Results

Clinical Trials, Low Blood Pressure, Multiple system atrophy (MSA), Neurogenic orthostatic hypotension (nOH), Parkinson's Disease, Parkinson’s disease, R&D, Rare Disorders, Serotonin And Norepinephrine Reuptake Inhibitors, Therapeutics

Theravance Biopharma announced mixed results from a study evaluating the use of ampreloxetine to reduce symptomatic neurogenic orthostatis hypotension (nOH).

April 5, 2022/by BioSpace

Lexicon, BridgeBio, Esperion, Pfizer, More Celebrate Wins at 71st ACC Meeting

AstraZeneca, BioSpace, Cholesterol, Clinical Data, Clinical Trial Endpoints, Elevated Low-Density Lipoprotein Cholesterol (LDL-C), Heart Attacks, Heart Failure with Reduced Ejection Fraction (HFrEF), Pfizer, Primary Endpoints, R&D, Regeneron Pharmaceuticals, Sanofi, Small-Interfering RNA (siRNA) Class, Strokes, TTR Amyloidosis (ATTR)

The 71st annual American College of Cardiology’s Scientific Session saw several wins – and some “mehs” led by some of biopharma’s largest companies, according to BioSpace.

April 4, 2022/by BioSpace

Reuters Health

West Virginia’s attorney general on April 4 urged a judge to hold Johnson & Johnson, Teva Pharmaceutical Industries Ltd., and AbbVie Inc.’s Allergen liable for causing a “tsunami” of opioid addiction in the state.

April 4, 2022/by Reuters Health

BMS Presents Robust Mavacamten Results in HCM Ahead of FDA Decision

Bristol Myers Squibb, Cardiac myosin inhibitors, Cardiovascular Disease, Clinical Trials, Hypertrophic cardiomyopathy (HCM), R&D, R&D, Research & Development

Bristol Myers Squibb announced results from an extended study to evaluate the long-term effects of taking the cardiovascular drug mavacamten.

April 4, 2022/by BioSpace

RedHill pill shows promise vs Omicron; mRNA vaccines appear effective in those with well-controlled HIV

mRNA in the spotlight as BioNTech finally makes a splash in cancer

Lilly’s lebrikizumab combined with topical corticosteroids showed significant improvements in disease severity for atopic dermatitis

Boehringer Ingelheim Addresses Ukraine Crisis while Projecting 15 Launches by 2025

FDA pulls authorization for GSK-Vir’s COVID therapy as BA.2 cases rise

With mRNA Advancing, Bancel Tells Friends “Don’t Die” in Next 10 Years

Theravance Narrows Focus to Multiple System Atrophy Subset Following Mixed Results

Lexicon, BridgeBio, Esperion, Pfizer, More Celebrate Wins at 71st ACC Meeting

West Virginia Says J&J, Drugmakers Created ‘Tsunami’ of Opioid Addiction

BMS Presents Robust Mavacamten Results in HCM Ahead of FDA Decision